1 |
Liang, K. W., C. T. Ting, S. C. Yin, Y. T. Chen, S. J. Lin, J. K. Liao and S. L. Hsu. 2006. Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury. Biochem. Pharmacol. 71, 806-817
DOI
ScienceOn
|
2 |
McVean, M., H. Xiao, K. Isobe, and J. C. Pelling. 2000. Increase in wild-type p53 stability and transactivational activity by the chemopreventive agent apigenin in keratinocytes. Carcinogenesis 21, 633-639
DOI
ScienceOn
|
3 |
Moon, Y., F. G. Bottone, M. F. McEntee, T. E. Eling. 2005. Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1. Mol. Cancer. Ther. 4, 1551-1558
DOI
ScienceOn
|
4 |
Moon, Y., M. Lee, and H. Yang. 2006. Involvement of early growth response gene 1 in the modulation of microsomal prostaglandin E synthase1 by epigallocatechin gallate in A549 human pulmonary epithelial cells. Biochem. Pharmacol. in press
DOI
ScienceOn
|
5 |
Pai, R., B. Soreghan.I. L. Szabo, M. Pavelka, D. Baatar, and A. S. Tarnawski. 2002. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8, 289-293
DOI
ScienceOn
|
6 |
Shao, J., B. M. Evers, and H. Sheng. 2004. Prostaglandin E2 synergistically enhances receptor tyrosine kinase- dependent signaling system in colon cancer cells. J. Biol. Chem. 279, 14287-14293
DOI
ScienceOn
|
7 |
Shao, J., C. Jung, C. Liu, and H. Sheng. 2005. Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer. J. Biol. Chem. 280, 26565-26572
DOI
ScienceOn
|
8 |
De Sousa, L. P., B. S. Brasil, B. M. Silva, M. H. Freitas, S. V. Nogueira, P. C. Ferreira, E. G. Kroon, and C. A. Bonjardim. 2005. Plasminogen/plasmin regulates c-fos and egr-1 expression via the MEK/ERK pathway. Biochem. Biophys. Res. Commun. 329, 237-245
DOI
ScienceOn
|
9 |
Dieckgraefe, B. K. and D. M. Weems. 1999. Epithelial injury induces egr-1 and fos expression by a pathway involving protein kinase C and ERK. Am. J. Physiol. 276, G322-G330
|
10 |
Fenton J. I., and N. G. Hord. 2004. Flavonoids promote cell migration in nontumorigenic colon epithelial cells differing in Ape genotype: implications of matrix metalloproteinase activity. Nutr. Cancer. 48, 182-188
DOI
ScienceOn
|
11 |
Fukuda, R., B. Kelly, and G. L. Semenza. 2003. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 63, 2330-2334
|
12 |
Hampton, T. 2005 NSAID studies abound in cancer research: drugs may have niche in prevention and treatment, JAMA. 293, 2579-2580
DOI
ScienceOn
|
13 |
Kune, G. A. 2000. Colorectal cancer chemoprevention: aspirin, other NSAID and COX-2 inhibitors. Aust. N. Z. J. Surg. 70, 452-455
DOI
|
14 |
Horinaka M, T. Yoshida, T. Shiraishi, S. Nakata, M. Wakada, and T. Sakai. 2006. The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol. Cancer. Ther. 5, 945-951
DOI
ScienceOn
|
15 |
Husain, S. S., I. L. Szabo, and A. S. Tamawski, 2002. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am. J. Gastroenterol. 97, 542-553
DOI
ScienceOn
|
16 |
Iczkowski, K. A. and C. G. Pantazis. 2003. Overexpression of NSAID-activated gene product in prostate cancer. Int. J. Surg. Pathol. 11, 159-166
DOI
ScienceOn
|
17 |
Baek, S. J., J. M. Horowitz and T. E. Eling. 2001. Molecular cloning and characterization of human non-steroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. J. Biol. Chem. 276, 33384-33392
DOI
ScienceOn
|
18 |
Baek, S. J., J. S. Kim, S. M. Moore, S. H. Lee, J. Martinez, J. and T. E. Eling. 2005. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an anti-tumorigenic protein. Mol. Pharmacol. 67, 356-364
DOI
ScienceOn
|
19 |
Baek, S. J., L. C. Wilson, C. H. Lee and T. E. Eling. 2002. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J. Pharmacol. Exp. Ther. 301, 1126-1131
DOI
ScienceOn
|
20 |
Bottone, F. G., Jr., S. J. Baek, J. B. Nixon, and T. E. Eling. 2002. Dially1 disulfide (DADS) induces the anti-tumorigenic NSAID-activated gene (NAG-1) by a p53-dependent mechanism in human colorectal HCT 116 cells. J. Nutr. 132, 773-778
DOI
|
21 |
Baek, S. J., J. S. Kim, J. B. Nixon, R. P. DiAugustine, and T. E. Eling. 2004. Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1. J. Biol. Chem. 279, 6883-6892
DOI
ScienceOn
|
22 |
Castellone, M. D., H. Teramoto, B. O. Williams, K. M. Druey and J. S. Gutkind. 2005. Prostaglandin E2 promotes colon cancer cell growth through a Cs-axin-beta-catenin signaling axis. Science 310, 1504-1510
DOI
ScienceOn
|
23 |
Chell, S., H. A. Patsos, D. Qualtrough, H. Z. AM, D. J. Hicks, A. Kaidi, I. R. Witherden, A. C. Williams, and C. Paraskeva. 2005. Prospects in NSAID-derived chemo-prevention of colorectal cancer. Biochem. Soc. Trans. 33, 667-671
DOI
ScienceOn
|
24 |
Chintharlapalli, S., S. Papineni, S. J. Baek, S. Liu, S. and S. Safe. 2005. 1,1-Bis(3'-indoly1)-1-(p-substitutedpheny1) methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. Mol. Pharmacol. 68, 1782-1792
|
25 |
Wang W, P. C. VanAlstyne, K. A. Irons, S. Chen, J. W. Stewart, and D. F. Birt. 2004. Individual and interactive effects of apigenin analogs on G2/M cell-cycle arrest in human colon carcinoma cell lines. Nutr. Cancer. 48, 106-114
DOI
ScienceOn
|